Image default
AI

Quantum to Present Storage Architecture Considerations for Machine Learning at ISC 2020 Digital

Quantum Corp. (NASDAQ: QMCO) today announced that Eric Bassier, Quantum’s senior director of product marketing, will present at the inaugural ISC 2020 Digital high performance computing (HPC) -focused event, held June 22 – 25, 2020.  Bassier’s participation in the online event underscores Quantum’s leadership in storing and managing large unstructured datasets that are common in the HPC community, and follows the addition of the ActiveScale™ object storage software and appliances to the company’s product portfolio earlier this year.

Bassier will discuss how the fields of AI and machine learning are at the forefront of driving innovation and discoveries across the globe. These fields generate massive datasets that require extremely fast processing, continuous analytics, as well as long-term protection and preservation. These requirements put pressure on traditional storage infrastructures, which are driving many research institutions to leverage new technologies including GPUs, NVMe, erasure-encoded object storage, and more. 

In his presentation, Bassier will discuss:

  • Key considerations for machine learning at scale.
  • Reference architectures based on customer deployments.
  • Options for the long-term preservation of machine learning data.

[Click to Tweet: Discover the storage architectures ideally suited for machine learning @QuantumCorp presentation #ISC20 https://bit.ly/37wGcN5]

“HPC environments commonly create extreme volumes of unstructured data, which need to be stored in durable, forever archives, enabling researchers and engineers to move seamlessly from raw data to analysis to actionable insights,” said Bassier.  “ISC 2020 Digital gathers some of the world’s foremost data-driven enterprises that are striving to manage, scale and protect their most valuable data.”

Related posts

Medsender Partners with Kareo

PR Newswire

Taiwan Innotech Expo 2020 to Showcase Deployments for Smart Future

PR Newswire

AI Therapeutics Starts Phase II LAM-002A Trial for COVID Patients

Business Wire